Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser1177/Thr497 of endothelial nitric oxide synthase in diabetic mice

Conclusions:
These results provide evidence that azilsartan prevents endothelial dysfunction in diabetic mice, more potently than does candesartan cilexetil. Azilsartan's higher affinity for and slower dissociation from AT1 receptors may underlie its efficacy in diabetic vascular dysfunction via a dual effect on uncoupled eNOS and on Nox.

Source: Cardiovascular Diabetology - January 31, 2014 Category: Cardiology Authors: Sachiko MatsumotoMichio ShimabukuroDaiju FukudaTakeshi SoekiKen YamakawaHiroaki MasuzakiMasataka Sata Source Type: research